Xgeva Articles
Amgen's Xgeva gets NICE backing for bone metastasis
24 October 2012
Denosumab reduces burden of giant-cell tumor of the bone
25 September 2012
UK's NICE continues to back Amgen's Xgeva for most cancer patients with bone metastases
17 August 2012
Denosumab superior to zoledronic acid for breast cancer patients with bone metastases
15 August 2012
UK's NICE takes second look at Amgen's Xgeva
12 June 2012
Four new drugs will change prostate cancer care, says US expert
19 February 2012
Global osteoporosis market report sees strong showing in China
1 February 2012
More cancer and HIV drugs added to Australian PBS
7 December 2011
Amgen’s Prolia increases bone mineral density over eight; new indications approved
20 September 2011
Amgen files Xgeva with FDA for additional indication
29 June 2011
Slew of good news from EMA advisory panel for Benlysta, Fampyra, Vibativ, Victrelis, Xgeva and Yervoy
23 May 2011
Amgen says Xgeva first drug to prevent spread of bone cancer in prostate cancer patients
19 May 2011
New therapies for metastatic disease addressed in updated NCCN Guidelines for breast cancer
15 March 2011
Intercell’s Travelers’ diarrhea vaccine and Lilly’s tasisulam flop; Amgen’s Xgeva looks good
14 December 2010
US FDA approves expanded use of Amgen’s bone drug denosumab, which could boost potential sales to $2.4 billion
19 November 2010
Showing 1-23 of 23 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
